Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Drummond

Jonsson

Rutten

Stargardt

. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ. 2011;12:263-271. doi:10.1007/s10198-010-0274-y

Medbelle. 2019 medicine price index. https://www.medbelle.com/medicine-price-index. Assessed November 30, 2019.

IMS Health Singapore. Building greater access to innovative medicines—what is next for Malaysia? An analysis of proposed reforms and a review of possible access schemes. https://www.phama.org.my/index.cfm?&menuid=86&parentid=6.

Drummond

Towse

. Is rate of return pricing a useful approach when value-based pricing is not appropriate? Eur J Health Econ. 2019;20:945-948. doi:10.1007/s10198-019-01032-7

Ahmad

. Enhancing sustainability in healthcare delivery—a challenge to the New Malaysia. Malays J Med Sci. 2019;26:1-4. doi:10.21315/mjms2019.26.1.1

Boo

. Competition beats medicine price controls, UK expert tells Malaysia. https://codeblue.galencentre.org/2019/12/09/competition-beats-medicine-price-controls-uk-expert-tells-malaysia/. Published December 9, 2019. Accessed April 24, 2020.

Berndt

Cockburn

. The hidden cost of low prices: limited access to new drugs in India. Health Affairs (Millwood). 2014;339. doi:10.1377/hlthaff.2013.1307

Is Dual Policy an Overarching Strategy for Medicine Price Controls in Malaysia?

Abstract

Get full access to this article

References